Alterity Therapeutics Limited (ASX:ATH)
Australia · Delayed Price · Currency is AUD 0.0110
+0.0010 (10.00%)
May 8, 2026, 4:10 PM AEST
Alterity Therapeutics Employees
Alterity Therapeutics had 9 employees as of June 30, 2025. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
737.38K AUD
Profits / Employee
-1.62M AUD
Market Cap
119.63M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 9 | -1 | -10.00% |
| Jun 30, 2024 | 10 | -1 | -9.09% |
| Jun 30, 2023 | 11 | -1 | -8.33% |
| Jun 30, 2022 | 12 | 1 | 9.09% |
| Jun 30, 2021 | 11 | -1 | -8.33% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Alterity Therapeutics News
- 3 days ago - Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 - GlobeNewsWire
- 10 days ago - Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update - GlobeNewsWire
- 12 days ago - Alterity Therapeutics Transcript: KOL event - Transcripts
- 13 days ago - Regulatory Update on Alterity Therapeutics (ATHE) and ATH434 Development - GuruFocus
- 13 days ago - Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study - Nasdaq
- 13 days ago - Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting - TheFly
- 13 days ago - Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy - GlobeNewsWire
- 18 days ago - Alterity Therapeutics (ATHE) Shows Promising Results in Phase 2 Trial for MSA - GuruFocus